Compare Amphastar Pharmaceuticals Inc (AMPH) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.55 (market cap $826.08M), while Yum! Brands, Inc. trades at $162.95 (market cap $45.08B). The key difference: Yum! Brands, Inc. is far larger — about 54.6× Amphastar Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 1.83% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | YUM | |
|---|---|---|
Market Cap | $826.08M | $45.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $168.16 |
52-Week Low | $16.87 | $138.21 |
Enterprise Value | $1.22B | $56.34B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
YUM trades at $163.54, up 0.71% with bullish technical signals and strong support at $158. Revenue grew to $8.21B in 2025 with a 20.48% net margin, though profit margins have slightly declined. The recent $2.7B Pizza Hut sale and $4B buyback authorization highlight strategic focus on KFC and Taco Bell growth. Cash flow from operations remains robust at $2.01B, supporting dividend payments and debt management.
Outlook is positive with analyst consensus target of $174 offering 6.4% upside, but high debt levels and competitive pressures pose risks. The stock's valuation at 26.38 P/E requires sustained earnings growth to justify further gains, making execution on digital initiatives and international expansion critical near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
